Rpg Life Sciences Ltd. (NSE: RPGLIFE, BSE: 532983) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,310 Cr, it ranks #902 by market cap among the 6,197 Indian listed companies on FinBizNet, and #30 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,569.00 (as of 16 Nov 2026), the share price is 17.9% below its 52-week high of ₹3,127.80 and 48.2% above its 52-week low of ₹1,733.00. The share price is up 6.3% over one year and down 9.9% over three months.
| Current Price | ₹2,569.00 |
|---|---|
| Market Cap | ₹4,310 Cr |
| NSE Symbol | RPGLIFE |
| BSE Code | 532983 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 37.5 |
| Return on Equity | 20.28% |
| Return on Assets | 10.84% |
| 52-Week Range | ₹1,733.00 – ₹3,127.80 |
| 1-Year Price Change | +6.3% |
| 3-Month Price Change | -9.9% |
| Beta (1Y) | 0.06 |
| Dividend Yield | 0.92% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.rpglifesciences.com |
| Revenue | ₹212 Cr |
|---|---|
| Net Profit | ₹28 Cr |
| Net Margin | 13.3% |
| EPS (Basic) | ₹17.07 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Rpg Life Sciences Ltd. reported revenue of ₹212 Cr in Q2 FY27, up 8.2% from ₹196 Cr in Q1 FY27. It posted a net profit of ₹28 Cr for the quarter, against a net profit of ₹31 Cr in Q1 FY27 (down 8.3%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹177 Cr (Q4 FY26) to ₹212 Cr (Q2 FY27). The company was profitable in each of these 4 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹212 Cr | ₹28 Cr | 13.3% |
| Q1 FY27 | ₹196 Cr | ₹31 Cr | 15.7% |
| Q4 FY26 | ₹177 Cr | ₹30 Cr | 16.9% |
| Q3 FY26 | ₹180 Cr | ₹22 Cr | 12.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 72.95% of Rpg Life Sciences Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 40.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was
1. Pharmaceuticals-This segment manufactures and markets branded formulations, generics, and active pharmaceutical ingredients. 2. Investment & Lending-0 3. Corporate-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Rpg Life Sciences Ltd. | ₹4,310 Cr | 37.5 | 20.28% | ₹212 Cr | +6.3% |
Listed by market capitalisation. Ratios are shown for context only.
Rpg Life Sciences Ltd. is trading at ₹2,569.00, with a market capitalisation of ₹4,310 Cr.
Rpg Life Sciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Rpg Life Sciences Ltd. has a P/E of 37.5 and a return on equity of 20.28%.
Rpg Life Sciences Ltd. is listed on the NSE under the symbol RPGLIFE and on the BSE under the scrip code 532983.
Rpg Life Sciences Ltd.'s share price is up 6.3% over one year and down 9.9% over three months. Its 52-week range is ₹1,733.00 to ₹3,127.80.
In Q2 FY27, Rpg Life Sciences Ltd. reported revenue of ₹212 Cr and net profit of ₹28 Cr, with basic EPS of ₹17.07 (consolidated, parsed from the company's exchange filing).
Promoters held 72.95% of Rpg Life Sciences Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.